Inclusion Criteria:

- Age ≥18 years

- Diagnosis of NF2

- Presence of vestibular schwannomas

- Evidence of progressive increase in vestibular schwannoma size or worsening hearing
loss due to vestibular schwannoma

- Adequate functional status (Karnofsky Performance Score ≥60)

- Adequate bone marrow, liver, kidney function

- If sexually active, willingness to use effective barrier or medical contraception

- For women of childbearing potential, no pregnancy or breast-feeding

- Discontinuation of other therapies (except corticosteroids) for the treatment of NF2
and resolution of any acute toxic effects of prior therapies

- Willingness and ability to comply with scheduled visits, drug administration plan,
laboratory tests, other study procedures, and study restrictions

- Willingness to provide informed consent

Exclusion Criteria:

- Uncontrolled hypertension, major bleeding, HIV infection, or recent acute
cardiovascular event

- Prior exposure to another anti-angiogenic therapy (eg, bevacizumab, sunitinib)